pI: 7.3644 |
Length (AA): 483 |
MW (Da): 58085 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 4 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
38 | 218 | 4uos (A) | 7 | 183 | 27.00 | 0.24 | 0.96 | 0.640482 | -0.55 |
82 | 241 | 5szg (A) | 1848 | 1983 | 35.00 | 0.91 | 0.06 | 0.407071 | 0.29 |
244 | 419 | 3f57 (A) | 1688 | 1893 | 10.00 | 0 | 0.04 | 0.344318 | -0.22 |
266 | 373 | 5j0l (D) | 5 | 120 | 29.00 | 0.7 | 0.23 | 0.672718 | -1.92 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | Procyclic, Bloodstream Form. | Siegel TN |
Siegel TN | Genome-wide analysis of mRNA abundance in two life-cycle stages of Trypanosoma brucei and identification of splicing and polyadenylation sites. |
Ortholog group members (OG5_130267)
Species | Accession | Gene Product |
---|---|---|
Dictyostelium discoideum | DDB_G0276103 | actin binding protein |
Drosophila melanogaster | Dmel_CG11449 | CG11449 gene product from transcript CG11449-RA |
Echinococcus granulosus | EgrG_001047400 | coiled coil domain containing 19 |
Echinococcus multilocularis | EmuJ_001047400 | coiled coil domain containing 19 |
Giardia lamblia | GL50803_13372 | Spindle pole protein, putative |
Homo sapiens | ENSG00000213085 | cilia and flagella associated protein 45 |
Leishmania braziliensis | LbrM.10.1260 | hypothetical protein, conserved |
Leishmania donovani | LdBPK_101240.1 | Tumour suppressor, Mitostatin, putative |
Leishmania infantum | LinJ.10.1240 | hypothetical protein, conserved |
Leishmania major | LmjF.10.1150 | hypothetical protein, conserved |
Leishmania mexicana | LmxM.10.1150 | hypothetical protein, conserved |
Mus musculus | ENSMUSG00000026546 | cilia and flagella associated protein 45 |
Neospora caninum | NCLIV_056330 | GI11378, related |
Schistosoma japonicum | Sjp_0003630 | Conserved hypothetical protein |
Schistosoma mansoni | Smp_172140 | hypothetical protein |
Schmidtea mediterranea | mk4.008934.04 | CCDC19 protein |
Schmidtea mediterranea | mk4.000702.07 | CCDC19 protein |
Schmidtea mediterranea | mk4.000101.09 | CCDC19 protein |
Schmidtea mediterranea | mk4.009249.05 | CCDC19 protein |
Trypanosoma brucei gambiense | Tbg972.8.4380 | hypothetical protein, conserved |
Trypanosoma brucei | Tb927.8.4580 | Basal body protein |
Trypanosoma congolense | TcIL3000_8_4420 | hypothetical protein, conserved |
Trypanosoma cruzi | TcCLB.509571.50 | Basal body protein |
Trypanosoma cruzi | TcCLB.511409.50 | Basal body protein |
Toxoplasma gondii | TGME49_312980 | hypothetical protein |
Trichomonas vaginalis | TVAG_314720 | coiled-coil domain-containing protein, putative |
Trichomonas vaginalis | TVAG_397500 | splicing factor, arginine/serine-rich, putative |
Trichomonas vaginalis | TVAG_046480 | GRIP1-associated protein, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.8.4580 this record | Trypanosoma brucei | significant loss of fitness in bloodstream forms (3 days) | alsford |
Tb927.8.4580 this record | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb927.8.4580 this record | Trypanosoma brucei | significant loss of fitness in procyclic forms | alsford |
Tb927.8.4580 this record | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
TGME49_312980 | Toxoplasma gondii | Essentiality uncertain | sidik |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
Affected Entity | Phenotypic quality | Occurs in | Occurs at | Evidence | Observed in | Drugs/Inhibitors |
---|---|---|---|---|---|---|
cell proliferation (GO:0008283) | decreased (PATO:0000468) | bloodstream stage trypomastigotes (PLO:0027) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | decreased cell proliferation (significant loss of fitness) in bloodstream forms (stage 6 days). | References: | 21363968 | |
cell proliferation (GO:0008283) | decreased (PATO:0000468) | procyclic (PLO:0034) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | decreased cell proliferation (significant loss of fitness) in differentiation of procyclic to bloodstream forms . | References: | 21363968 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
1 literature reference was collected for this gene.